This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
by Zacks Equity Research
INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Teva Pharmaceutical Industries, Visa, American Express, Liberty Latin America and Sirius XM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Teva Pharmaceutical Industries, Visa, American Express, Liberty Latin America and Sirius XM
5 Must-Watch Warren Buffett Stocks for 2019
by Tirthankar Chakraborty
We have selected five of Oracle of Omaha's favored companies that are likely to make the most of this year. Most of these companies belong to sectors such as health care, financials and communication services.
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
by Zacks Equity Research
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster
by Zacks Equity Research
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar
by Zacks Equity Research
Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.
Generic Industry on Path to Recovery: 3 Hot Picks for 2019
by Zacks Equity Research
The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.
Teva Stock Rises on Patent Settlement With Neos Therapeutics
by Zacks Equity Research
Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.
Company News For Dec 27, 2018
by Zacks Equity Research
Companies In The News Are: TEVA,NEOS,JD,EXPE,INTC,MAR
Lilly's Shares Rise on Robust 2019 View, Dividend Hike
by Zacks Equity Research
Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.
Allergan Drops, Stops Textured Breast Implant Sales in Europe
by Zacks Equity Research
Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.
Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teva Reports Positive Top-Line Data for Migraine Candidate
by Zacks Equity Research
Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.
Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug
by Zacks Equity Research
Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.
Teva (TEVA) Stock Poised to Record Big Gains in 2019?
by Zacks Equity Research
Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.
Generic Drugmakers Down on Allegations of Price Fixing
by Zacks Equity Research
An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.
Roche's Kadcyla Halves Death Risk in Breast Cancer Study
by Zacks Equity Research
Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.
Mylan Expands Recall of Valsartan to All Unexpired Lots
by Zacks Equity Research
Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.
Roche Announces Positive Data on Venclexta/Venclyxto at ASH
by Zacks Equity Research
Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018
by Zacks Equity Research
AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH) annual meeting.
Novartis' Gilenya Approved in EU for Expanded Population
by Zacks Equity Research
Novartis (NVS) gains the EU approval for MS drug Gilenya for children who are 10-17 years old with relapsing-remitting forms of multiple sclerosis.
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma
by Zacks Equity Research
Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.
Galapagos' Osteoarthritis Candidate Gets Fast Track Status
by Zacks Equity Research
Galapagos' (GLPG) GLPG1972/S201086 gets Fast Track designation by the FDA for the treatment of osteoarthritis.
Teva (TEVA) Launches First Generic Version of Mylan's EpiPen
by Zacks Equity Research
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.